6 citations
,
September 2024 in “BMC Pulmonary Medicine” This study demonstrated that CEP may effectively treat pulmonary fibrosis by inhibiting fibroblast activation through regulating macrophage M2 polarization and decreasing fibrosis-associated factors, suggesting a new avenue for future research in this area.
8 citations
,
August 2022 in “Pharmaceutics” This study found that erythrocyte-anchored CPA-encapsulated nanoparticles improved the delivery and accumulation of Cepharanthine in the lungs, enhancing its effectiveness in treating acute lung injury by reducing inflammatory responses.
14 citations
,
April 2022 in “Molecules” This study found that pulmonary delivery of cepharanthine significantly improved bioavailability and may provide protective effects against pulmonary fibrosis related to COVID-19 infection in a rat model.
6 citations
,
May 2023 in “Molecules” In this study, dry powder inhalers containing Cepharanthine were administered to rats with acute lung injury, significantly reducing pulmonary edema, hemorrhage, and inflammatory markers, suggesting its potential as an effective anti-inflammatory treatment when inhaled directly into the lungs.
15 citations
,
July 2022 in “Frontiers in Pharmacology” This study suggests that Cepharanthine, a monomer in traditional Chinese medicine, may help treat COVID-19 by affecting multiple signaling pathways, and that TNF and IL-17 inhibitors used in rheumatoid arthritis, ankylosing spondylitis, and gouty arthritis might also be beneficial.